Acalabrutinib
September 29, 2023
Acalabrutinib may be taken alone or in combination with obinutuzumab as a preferred initial (first-line) treatment, or alone as a second- or thirdline treatment.
Acalabrutinib may be taken alone or in combination with obinutuzumab as a preferred initial (first-line) treatment, or alone as a second- or thirdline treatment.
This real-world study found that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib were more likely to need to change therapies or add an additional therapy compared with patients treated with ibrutinib.
Bruton tyrosine kinase (BTK) degraders are a new therapeutic area that might be able to overcome mutations that cause resistance to BTK inhibitors.
Acalabrutinib produced durable responses in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at higher risk of disease progression.
Follow-up results from a phase 1/2 trial of acalabrutinib in CLL / SLL patients further confirm that acalabrutinib is safe & effective.
Patients with acalabrutinib had lower discontinuation rates and a prolonged time to discontinuation compared to pts treated with ibrutinib.
Final data from a phase 1/2 clinical trial with six years of follow-up show that first-line acalabrutinib produces high response rates and rapid, durable responses in patients with CLL
I am grateful to Nathan Vardi for illuminating this incredible story’s corners, and I highly recommend his book.
Our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute. They discussed the results of a new study looking at whether combining the anti-CD20 monoclonal antibody obinutuzumab with the BTK inhibitor acalabrutinib provided any additional survival benefit.